Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.76 |
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.76 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31341232 | 0.87 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL24187739 | 0.87 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL27738181 | 0.84 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL31341334 | 0.84 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL23794761 | 0.83 | HSD17B1 (0.62) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL1222603 | 0.82 | ALDH1A1 (0.72) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL23794611 | 0.82 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL23794763 | 0.82 | HSD17B1 (0.57) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL16703124 | 0.82 | CSNK1D (0.53) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL1193921 | 0.81 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-3877384-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-09-15 | — | — | EP | disclosed |
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | disclosed |
| CN-112969698-A | Chemical compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| EP-1797065-A4 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1797065-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | NPC1 3330/4885RAB9A 3434/4885SMN1; SMN2 281/4885 |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | WNT1, WNT3, WNT3A | NPC1 3617/4885RAB9A 613/4885SMN1; SMN2 4735/4885 |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | NPC1 688/4885RAB9A 3846/4885SMN1; SMN2 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.